Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 ...

China’s Harbour BioMed has launched a new biotech to develop bispecific antibodies focused on the holy grail of next-gen ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Tech firm Clario is boosting its electronic clinical outcome assessment (eCOA) offerings by acquiring the ...

Johnson & Johnson MedTech has secured an FDA clearance for new artificial intelligence-powered guidance systems to support ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Emergent BioSolutions is investing in Swiss biotech Rocketvax, inking a deal designed to fuel the preclinical company’s R&D. | Emergent BioSolutions is investing in Swiss biotech Rocketvax, inking a ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta ...

Funding granted to researchers by the National Institutes of Health (NIH) powered $94.58 billion in economic activity across ...